Author:
Ahmad Iqrar,Pawara Rahul,Pathan Asama,Patel Harun
Publisher
Springer Nature Singapore
Reference60 articles.
1. Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, Sakamoto J, Matsumoto N, Miura T, Matsumura K, Seki N, Inaba T, Kawasaki H, Yamaguchi T, Kakefuda R, Nanayama T, Kurachi H, Hori Y, Yoshida T, Kakegawa J, Watanabe Y, Gilmartin AG, Richter MC, Moss KG, Laquerre SG (2011) Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate). ACS Med Chem Lett 2(4):320–324
2. Ahmad I, Shaikh M, Surana S, Ghosh A, Patel H (2020) p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. J Biomol Struct Dyn 11:1–14
3. AstraZeneca (n.d.). https://www.drugs.com/newdrugs/tagrisso-osimertinib-receives-fda-full-approval 4508.html (Assessed on 8/9/2020)
4. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494–6501
5. Caporuscio F, Tinivella A, Restelli V, Semrau MS, Pinzi L, Storici P, Broggini M, Rastelli G (2018) Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. Future Med Chem 10(13):1545–1553